| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032247806 |
| P356 | DOI | 10.1007/S40262-013-0115-0 |
| P698 | PubMed publication ID | 24218006 |
| P2093 | author name string | Stephan Krähenbühl | |
| Manuel Haschke | |||
| Massimiliano Donzelli | |||
| Christoph Noppen | |||
| Adrian Derungs | |||
| Lana Nezic | |||
| Maria-Giovanna Serratore | |||
| P2860 | cites work | Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174 | Q74463049 |
| Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors | Q77921996 | ||
| Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot | Q83213156 | ||
| Role of CYP2C19 polymorphisms in patients with endometriosis | Q84008046 | ||
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| Sample size determination for proving equivalence based on the ratio of two means for normally distributed data | Q31903329 | ||
| Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors | Q32064655 | ||
| Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. | Q33269667 | ||
| Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers | Q33810432 | ||
| Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies | Q34447046 | ||
| Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. | Q35825950 | ||
| Drug metabolism and variability among patients in drug response | Q36139862 | ||
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach | Q36720920 | ||
| Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial | Q36737411 | ||
| Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping | Q36922212 | ||
| Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system | Q39588040 | ||
| Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. | Q39853696 | ||
| Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes | Q41397855 | ||
| Comparison of plasma and saliva levels of metoprolol and oxprenolol | Q42024340 | ||
| A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study | Q42284131 | ||
| Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity | Q42780160 | ||
| An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. | Q43647195 | ||
| The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity | Q43775254 | ||
| Assessment of cytochrome P450 activity by a five-drug cocktail approach | Q43806811 | ||
| Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype | Q43874208 | ||
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity | Q44391267 | ||
| The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. | Q44481060 | ||
| Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". | Q44637323 | ||
| CYP2C9 genetic variants and losartan oxidation in a Turkish population. | Q44936830 | ||
| Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies | Q45141296 | ||
| Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients | Q46466409 | ||
| Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers | Q46720498 | ||
| Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study | Q46731232 | ||
| Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial | Q46981888 | ||
| Sample size determination for bioequivalence assessment using a multiplicative model | Q47406463 | ||
| Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping | Q48234146 | ||
| Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo | Q48610657 | ||
| Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. | Q51432740 | ||
| Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. | Q53325348 | ||
| Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations | Q67564635 | ||
| The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog | Q72317932 | ||
| Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes | Q73846452 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 271-282 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots | |
| P478 | volume | 53 |
| Q40405015 | A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail |
| Q38560254 | Alternative Sampling Strategies for Cytochrome P450 Phenotyping. |
| Q88695273 | Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects |
| Q37424646 | Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail |
| Q64950561 | Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. |
| Q88313993 | Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What? |
| Q64121841 | Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen |
| Q36460560 | Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study |
| Q47278098 | Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects |
| Q38754924 | Endogenous Probes for Drug Transporters: Balancing Vision With Reality |
| Q90344656 | Limited Sampling Modeling for Estimation of Phenotypic Metrics for CYP Enzymes and the ABCB1 Transporter Using a Cocktail Approach |
| Q92077259 | No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study |
| Q92525221 | Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacot |
| Q52315457 | Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. |
| Q49637368 | The effect of CYP1A2 gene polymorphism on the metabolism of theophylline |
| Q40996401 | Use of microdose phenotyping to individualise dosing of patients |
| Q49060953 | Why dried blood spots are an ideal tool for CYP1A2 phenotyping |
Search more.